Clinical Trial News and Research

RSS

India's DBT, Bharat Biotech announce positive Phase III clinical trial results of rotavirus vaccine

The Government of India's Department of Biotechnology and Bharat Biotech announced positive results from a Phase III clinical trial of a rotavirus vaccine developed and manufactured in India.

14 May 2013

NCCC doctors find effective drug combination to treat chronic lymphocytic leukemia

Doctors at Dartmouth-Hitchcock's Norris Cotton Cancer Center have found a combination of drugs to potentially treat chronic lymphocytic leukemia more effectively.

14 May 2013

UNM Cancer Center to participate in Phase 3 clinical trial of novel treatment for men with prostate cancer

The University of New Mexico Cancer Center is among a few select institutions nationwide participating in a Phase 3 clinical trial studying a novel treatment for men with newly diagnosed, localized prostate cancer.

13 May 2013

John Theurer to host 9th annual neuro-oncology symposium on May 17

John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 cancer centers, will host its Ninth Annual Neuro-Oncology Symposium on Friday, May 17th from 8:00am-1:00pm. Experts from MD Anderson, Memorial Sloan Kettering Cancer Center, Penn State Milton S. Hershey Medical Center, and the Cleveland Clinic will present advances in multidisciplinary care for cancers of the central nervous system.

10 May 2013

Mouse study shows leukemia halts accumulation of toxic proteins linked to Parkinson's disease

Researchers at Georgetown University Medical Center have used tiny doses of a leukemia drug to halt accumulation of toxic proteins linked to Parkinson's disease in the brains of mice. This finding provides the basis to plan a clinical trial in humans to study the effects.

10 May 2013

Operating without interrupting warfarin treatment during cardiac device surgery reduces hematomas

A new Canadian study shows that operating without interrupting warfarin treatment at the time of cardiac device surgery is safe and markedly reduces the incidence of clinically significant hematomas compared to the current standard of care.

10 May 2013

Severe anorexia nervosa improves with modification of standard goals, treatment methods

A new, multinational randomized clinical trial has found that patients with severe and enduring anorexia nervosa will not only stick with treatments but also make significant improvements with just a slight modification of the standard goals and methods of treatment.

10 May 2013

Lexicon Pharmaceuticals advances Phase 2 clinical trial of LX4211 in patients with type 1 diabetes

Lexicon Pharmaceuticals, Inc. announced today that it is progressing into the placebo-controlled portion of its Phase 2 clinical trial of LX4211 in patients with type 1 diabetes, having successfully completed the open-label, pioneer portion of the trial.

10 May 2013

InSite Vision starts patient enrollment in confirmatory Phase 3 clinical trial of BromSite

InSite Vision Incorporated today announced that patient enrollment has begun in the confirmatory Phase 3 clinical trial of BromSite (ISV-303) for the reduction of inflammation and pain after cataract surgery.

10 May 2013

Trevena, Forest sign collaborative agreement to develop TRV027 for treatment of ADHF

Trevena, Inc., a clinical stage pharmaceutical company and the leader in the discovery and development of G-protein coupled receptor biased ligands, and Forest Laboratories Holding Limited, a subsidiary of Forest Laboratories Inc., an international pharmaceutical company, announced today that they have entered into a collaborative licensing option agreement for the development of TRV027, an AT1R biased-ligand that recently completed Phase 2a clinical trials.

9 May 2013

Patients with ASPS appear to benefit from anti-cancer drug, cediranib

Patients with advanced alveolar soft part sarcoma (ASPS), a rare cancer, achieved some control of their disease using an experimental anti-cancer drug called cediranib.

8 May 2013

Protein tumor necrosis factor-alpha is a powerful weapon to control cancer

The protein tumor necrosis factor-alpha (TNF-alpha) is a powerful weapon in the arsenal to control cancer. Unfortunately, as is the case with many potent cancer therapies, the use of TNF-alpha as an anti-cancer therapy has been severely limited.

8 May 2013

Study shows patient selection based on biosamples makes clinical trials more efficient, reduces costs

Researchers at Moffitt Cancer Center say identifying and selecting participants for phase II cancer clinical trials from a centralized warehouse of patient-donated biological data expedites participant accrual, reduces trial size, saves money, and may speed test drugs through the drug development pipeline.

8 May 2013

Elixir Medical receives FDA approval to initiate patient enrollment in EXCELLA III clinical trial in US

Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that it has received approval from the Food and Drug Administration to initiate patient enrollment in the EXCELLA III clinical trial in the United States at up to 50 institutions with conditions to be addressed in parallel.

8 May 2013

Idera to present data from Phase 2 trial of IMO-3100 in patients with psoriasis at IID 2013

Idera Pharmaceuticals today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis Area Severity Index scores in patients with moderate to severe plaque psoriasis following four weeks of treatment with the Toll-like Receptor antagonist IMO-3100.

8 May 2013

New VLP vaccine candidate produced for H7N9 virus

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that it has successfully produced a new VLP vaccine candidate for the H7N9 virus that is responsible for the current influenza outbreak in China.

8 May 2013

Immunoglobulin fails to meet co-primary endpoints in Phase III clinical study, Baxter reports

Baxter International Inc. today announced that its Phase III clinical study of immunoglobulin did not meet its co-primary endpoints of reducing cognitive decline and preserving functional abilities in patients with mild to moderate Alzheimer's disease.

From Baxter International Inc. 8 May 2013

New skin cancer drug successfully tested in humans

A new class of drug targeting skin cancer's genetic material has been successfully tested in humans for the first time, opening the way to new treatments for a range of conditions from skin cancers to eye diseases.

8 May 2013

Janssen enrolls patients in expanded access program for mantle cell lymphoma

Janssen Research & Development, LLC (Janssen) today announced patients are now enrolling in a multicenter, open-label expanded access program (EAP) in the United States for the investigational oral Bruton's Tyrosine Kinase (BTK) inhibitor ibrutinib, which is being jointly developed by Janssen and Pharmacyclics, Inc.

7 May 2013

Anavex invited to submit funding application for Phase 2a trial of ANAVEX 2-73

Anavex Life Sciences Corp. ("Anavex") (OTCQB: AVXL) today announced that it has been invited to submit a full grant application to the Alzheimer's Drug Discovery Foundation ("ADDF") for a Phase 2a trial of ANAVEX 2-73.

7 May 2013

Clinical Trial News and Research

India's DBT, Bharat Biotech announce positive Phase III clinical trial results of rotavirus vaccine

NCCC doctors find effective drug combination to treat chronic lymphocytic leukemia

UNM Cancer Center to participate in Phase 3 clinical trial of novel treatment for men with prostate cancer

John Theurer to host 9th annual neuro-oncology symposium on May 17

Mouse study shows leukemia halts accumulation of toxic proteins linked to Parkinson's disease

Operating without interrupting warfarin treatment during cardiac device surgery reduces hematomas

Severe anorexia nervosa improves with modification of standard goals, treatment methods

Lexicon Pharmaceuticals advances Phase 2 clinical trial of LX4211 in patients with type 1 diabetes

InSite Vision starts patient enrollment in confirmatory Phase 3 clinical trial of BromSite

Trevena, Forest sign collaborative agreement to develop TRV027 for treatment of ADHF

Patients with ASPS appear to benefit from anti-cancer drug, cediranib

Protein tumor necrosis factor-alpha is a powerful weapon to control cancer

Study shows patient selection based on biosamples makes clinical trials more efficient, reduces costs

Elixir Medical receives FDA approval to initiate patient enrollment in EXCELLA III clinical trial in US

Idera to present data from Phase 2 trial of IMO-3100 in patients with psoriasis at IID 2013

New VLP vaccine candidate produced for H7N9 virus

Immunoglobulin fails to meet co-primary endpoints in Phase III clinical study, Baxter reports

New skin cancer drug successfully tested in humans

Janssen enrolls patients in expanded access program for mantle cell lymphoma

Anavex invited to submit funding application for Phase 2a trial of ANAVEX 2-73

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer